Skip to content

Join our community and subscribe to our free weekly newsletter

Subscribe
  • Latest News
    • Articles
    • Live Talks
    • Trials Update
  • Prevention & Risk Factors
    • Science-Backed Dementia Prevention
    • Alzheimer’s Genetics & Risk Factors
    • Menopause
    • Long COVID
  • Dementias
    • Alzheimer’s Disease
    • Vascular Dementia
    • Frontotemporal Dementia (FTD)
    • Lewy Body Dementia
    • Traumatic Brain Injury & CTE
  • Brain Disorders
    • Mild Cognitive Impairment (MCI)
    • Parkinson’s Disease
  • Getting Diagnosed
    • Diagnosis
    • Journey to Diagnosis
    • Genetic Testing
    • Alzheimer’s Biomarkers
    • Diversity and Dementia
  • Caregivers
    • Caregiver Voices
  • Learning Guides

Phil Gutis

  • Phil’s Journal: An IRL Example of Racism’s Affects on Cognition

  • Phil’s Journal

    Phil’s Journal: Making Space for the Layperson at Scientific Conferences

  • dr laura baker aaic exercise Large

    Phil’s Journal: Exercise Protects the Brain From MCI, But…

  • legos alzheimers phil gutis

    Phil’s Journal: An Alzheimer’s Story In LEGOs

  • Phil’s Journal

    Phil’s Journal: Reflections on AAIC, Day One

  • alzheimer's blood test

    Alzheimer’s Blood Tests Take Another Step Forward

  • Biogen aducanumab Aduhelm clinical trial participant Phil Gutis

    Phil’s Journal: Bringing the Patient’s Perspective to AAIC

  • Biogen aducanumab Aduhelm clinical trial participant Phil Gutis

    Phil’s Journal: The Face of Alzheimer’s Is Changing — Are We Ready?

  • aducanumab dementia

    Phil’s Journal: What’s Next for the Aducanumab Clinical Trial Rollercoaster?

  • With the #MoreTime campaign, the Alzheimer’s Association has gone all in on aducanumab, the controversial new Alzheimer’s drug produced by Biogen and Eisai.

    Alzheimer’s Association All In On Not-Yet-Approved Aducanumab

  • Phil’s Journal: A Lesson on Living With Alzheimer’s, Courtesy of My Dog

  • Jason Karlawish

    ‘The Problem of Alzheimer’s’ Makes Us Mad—In a Good Way

  • sumifilam alzheimers

    Cassava’s Simufilam: Who to Believe—Wall Street or Alzheimer’s Researchers?

  • Phil Gutis aducanumab Alzheimer's FDA approval snag

    FDA Delays Aducanumab Decision

  • Phil Gutis aducanumab Alzheimer's FDA approval snag

    Phil’s Journal: Reflections on Alzheimer’s Drug Aducanumab’s Latest Snag

Previous123Next

Sign up for our weekly newsletter

Subscribe to get the latest and most trusted brain health science and news, straight to your inbox.

Sign Up

Copyright © 2026 Being Patient

Join Our Community

Get brain health and dementia news, storytelling, and expert insights right to your inbox. Sign up for our free weekly newsletter.

You're in! Thanks for subscribing — our free weekly newsletter is coming your way.
You’re already subscribed to our newsletter.

About Being Patient

  • Advisors
  • Contribute
  • Meet the Team
  • Partnerships
  • Contact Us
  • Press
  • Glossary

Legal

  • Terms & Conditions
  • Privacy Policy
  • AI Policy
  • Republishing Our Content
Copyright © 2026 Being Patient

Social Media

  • Instagram 
  • Facebook
  • LinkedIn
  • YouTube
  • TikTok
  • X
Copyright © 2026 Being Patient

Page load link
Go to Top